Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ: HOWL), recently finalized a series of common stock sales totaling approximately $154,525. These transactions were executed over a three-day window between April 27 and April 29, 2026. The disposals were carried out under the framework of a pre-arranged Rule 10b5-1 trading plan, which had been established on March 26, 2026.
The timing of these sales coincides with a period of volatility for the company's equity. According to InvestingPro data, the stock has experienced a 27% decline over the past week, with shares currently trading at a level of $0.68. The specific details of the three-day selling period are as follows:
- April 27: Through various entities, Evnin sold 53,940 shares. These were traded at a weighted average price of $0.85 per share, with individual transaction prices fluctuating between $0.818 and $0.8788.
- April 28: An additional 95,412 shares were sold at a weighted average price of $0.73 per share. The prices for these transactions ranged from $0.673 to $0.82.
- April 29: The final tranche involved the sale of 56,559 shares at a weighted average price of $0.69 per share, with individual prices falling between $0.68 and $0.75.
These shares were held indirectly through several entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Evnin maintains several leadership roles within these structures, serving as a member of AM LLC, a Managing Director of BV LLC (the direct and indirect general partner of BV 2014 and BV 2014(B), and manager of AM BV2014), and a manager of MPM OIF GP (the general partner of MPM OIF). Following the conclusion of these sales, Evnin's indirect holdings in Werewolf Therapeutics common stock stand at 1,953,949 shares.
Despite the recent downward pressure on the share price, InvestingPro analysis indicates that the stock appears to be undervalued based on its Fair Value assessment. This valuation perspective is supported by the company's current balance sheet, which shows that Werewolf Therapeutics holds more cash than debt.
The director's transactions occur as Werewolf Therapeutics undergoes significant organizational and strategic changes. The company has officially announced it is exploring strategic alternatives to improve stockholder value. To facilitate this process, the firm has engaged Piper Sandler & Co. as an exclusive financial advisor to evaluate several paths, including potential mergers, sales, or other types of strategic transactions.
In tandem with these strategic evaluations, Werewolf Therapeutics has implemented a substantial reduction in its workforce. This downsizing affects 64% of the company's employees and is part of a broader initiative to lower operating expenses. These layoffs received approval from the board of directors and are expected to be largely finalized in the near future.
Furthermore, the company is currently addressing regulatory compliance issues with the Nasdaq Stock Market. Werewolf Therapeutics received a deficiency notice after its common stock closed below the required $1.00 minimum bid price for 30 consecutive business days. While this notice does not have an immediate impact on the trading or listing of the stock, the company has a 180-day window to achieve compliance. To meet these requirements, the stock must trade at or above the $1.00 mark for at least 10 consecutive business days during that period.